drugset / Trial / NCT01669720
Adjuvant Aflibercept for Metastatic Colorectal Cancer
Phase 2
Terminated
10 enrolled
Brown University
Lifespan · collabMontefiore Medical Center · collabRhode Island Hospital · collabSanofi · collabThe Miriam Hospital · collabUniversity of California, San Diego · collabUniversity of Florida · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to evaluate if aflibercept can reduce the chance that metastatic (spread of) colorectal cancer can grow back after finishing standard treatment. The study will also look at the side effects of aflibercept and the effect on quality of life.
Timeline
- Start
- 2012-12
- Primary completion
- 2015-12
- Completion
- 2016-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aflibercept | Protein / enzyme biologic | 4 mg/kg | Intravenous |